Fiche société
University of Florida
Traitements, essais et publications liés.
Traitements14programmes
Essais7liés
Publications7liées
SourceDBlocale
Traitements
14| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Active biphasic pulse stimulation---Home SettingsThis project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| Active biphasic pulse stimulation---Stimulator OffThis project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| Active biphasic pulse stimulation---VIN BiphasicThis project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| AIDP — Automated Imaging Differentiation of ParkinsonismThe purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis. | Parkinson | À vérifier | À vérifier | United States, Canada | À vérifier |
| CangrelorThe primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging. | Maladie coronarienne | Phase 4 | À vérifier | United States | À vérifier |
| Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy PatientsThis pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue). | Myopathies | Non applicable | Traitement symptomatique | United States | À vérifier |
| TadalafilExamining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment. | Myopathies | Phase 2/3 | À vérifier | United States | À vérifier |
| VM100 Nutritional SupplementThis pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue). | Myopathies | Phase 2 | Traitement symptomatique | United States | À vérifier |
| TadalafilExamining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment. | Myopathies | Phase 2 | À vérifier | United States | À vérifier |
| TadalafilExamining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment. | Myopathies | Phase 2/3 | À vérifier | United States | À vérifier |
| AIDP — Automated Imaging Differentiation of ParkinsonismThe purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis. | Parkinson | À vérifier | À vérifier | United States, Canada | À vérifier |
| VM100 Nutritional SupplementThis pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue). | Myopathies | Phase 2 | Traitement symptomatique | United States | À vérifier |
| Active biphasic pulse stimulation---Home SettingsThis project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET. | Parkinson | Non applicable | À vérifier | United States | À vérifier |
| CangrelorThe primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging. | Maladie coronarienne | Phase 4 | À vérifier | United States | À vérifier |
Essais cliniques
7| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Cangrelor | Maladie coronarienne | Phase 4 | NCT07225842 | BIRDGE 2 — The Bridging Antiplatelet Therapy With Cangrelor 2 Study | RECRUITING |
| Active biphasic pulse stimulation---Home Settings | Parkinson | Non applicable | NCT03811405 | Physiology, Imaging and Modeling of Essential Tremor | COMPLETED |
| Metformin | Sclérose latérale amyotrophique | Phase 2 | NCT04220021 | Safety and Therapeutic Potential of the FDA-approved Drug Metformin for C9orf72 ALS/FTD | ACTIVE_NOT_RECRUITING |
| VM100 Nutritional Supplement | Myopathies | Phase 2 | NCT07766980 | Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients | RECRUITING |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| Tadalafil | Myopathies | Phase 2/3 | NCT05195775 | Tadalafil as Adjuvant Therapy for DMD | COMPLETED |
| Tadalafil | Myopathies | Phase 2 | NCT06290713 | Vasodilator and Exercise Study for DMD (VASO-REx) | RECRUITING |
Publications
7| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Tadalafil | Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS). | The aging male : the official journal of the International Society for the Study of the Aging Male | ||
| Tadalafil | Real-world outcomes of tadalafil plus mirabegron combination therapy in men with lower urinary tract symptoms and overactive bladder symptoms: a retrospective cohort study. | The aging male : the official journal of the International Society for the Study of the Aging Male | ||
| Tadalafil | Risk of glaucoma among patients using tadalafil for lower urinary tract symptoms: a multinational cohort study. | The British journal of ophthalmology | ||
| Tadalafil | Targeting canonical TGFβ/SMAD3 and ERK1/2 signaling in human valve interstitial cells to modulate immune-fibrotic responses in rheumatic heart disease. | Journal of physiology and biochemistry | ||
| Tadalafil | Erectile dysfunction severity and penile Doppler findings in pelvic fracture urethral injury: A descriptive cohort study. | Indian journal of urology : IJU : journal of the Urological Society of India | ||
| Tadalafil | Selective targeting phosphodiesterase-5 (PDE5): clinical progress, design strategies, and emerging prospects. | Journal of enzyme inhibition and medicinal chemistry | ||
| Tadalafil | PDE5A variation is associated with tadalafil response in men with diabetes mellitus and erectile dysfunction: a prospective proof-of-concept pharmacogenetic study. | The journal of sexual medicine |